Factors associated with progression of carcinoid heart disease

New England Journal of Medicine

Volumn 348, Issue 11, 2003, Pages 1005-1015

  Møller, Jacob E ^a   Connolly, Heidi M ^a   Rubin, Joseph ^a   Seward, James B ^a   Modesto, Karen ^a   Pellikka, Patricia A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANTINEOPLASTIC AGENT; SEROTONIN;

ABDOMINAL SCINTISCANNING; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CARCINOID; CARCINOID SYNDROME; CIRCULATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; HEART RIGHT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT PLANNING; VALVULAR HEART DISEASE;

AGED; CARCINOID HEART DISEASE; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART VALVE DISEASES; HUMANS; HYDROXYINDOLEACETIC ACID; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 0037434851     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa021451     Document Type: Article

References (25)

1. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79: 813-29.
2. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999;340:858-68.
3. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188-96.
4. Lundin L, Norheim I, Landelius J, Oberg K, Theodorsson-Norheim E. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 1988;77: 264-9.
5. Denney WD, Kemp WE Jr, Anthony LB, Oates JA, Byrd BF III. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am Coll Cardiol 1998;32:1017-22.
6. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790-5.
7. Rivera JM, Vandervoort PM, Morris E, Weyman AE, Thomas JD. Visual assessment of valvular regurgitation: comparison with quantitative Doppler measurements. J Am Soc Echocardiogr 1994;7:480-7.
8. Suzuki Y, Kambara H, Kadota K, et al. Detection and evaluation of tricuspid regurgitation using a real-time, two-dimensional, color-coded, Doppler flow imaging system: comparison with contrast two-dimensional echocardiography and right ventriculography. Am J Cardiol 1986;57:811-5.
9. Pennestri F, Loperfido F, Salvatori MP, et al. Assessment of tricuspid regurgitation by pulsed Doppler ultrasonography of the hepatic veins. Am J Cardiol 1984;54:363-8.
10. Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83:2293-301.
11. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med 1986;315:663-6.
12. Seuwen K, Magnaldo I, Pouyssegur J. Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. Nature 1988;335:254-6.
13. Roy A, Brand NJ, Yacoub MH. Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves. J Heart Valve Dis 2000; 9:256-61.
14. Rajamannan NM, Caplice N, Anthikad F, et al. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis 2001;10:827-31.
15. Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334:246-54.
16. Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor sub-types and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994;93:1321-5.
17. di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: a study by the Italian Trials in Medical Oncology Group. Cancer 1996;77:402-8.
18. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17:600-6.
19. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors: a prospective phase II study in 24 patients. Cancer 1993;71:2624-30.
20. Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001;91:1543-8.
21. Oberg K, Norheim I, Lundqvist G, Wide L. Cytotoxic treatment in patients with malignant carcinoid tumors: response to streptozocin - alone or in combination with 5-FU. Acta Oncol 1987;26:429-32.
22. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001;12:Suppl 2:S111-S114.
23. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid turnout. Lancet 1998;352:799-805.
24. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990;322:810-6.
25. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Malave JJ. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 1992;66:198-203.